On Jun 29, 2018 Gilead Sciences (NASDAQ:GILD) with $93 Target Analyzed by Raymond James.

June 29, 2018 - By Jeanette Garcia

Gilead Sciences, Inc. (NASDAQ:GILD) Corporate Logo

During Q1 2018 the big money sentiment increased to 0.88. That’s change of 0.08, from 2017Q4’s 0.8. 71 investors sold all, 519 reduced holdings as Gilead Sciences, Inc. ratio is positive. 404 grew positions while 114 funds took positions. Funds hold 976.44 million shares thus 0.39% more from 2017Q4’s 972.68 million shares.

Bristol John W Communication, New York-based fund reported 2,900 shs. 36,000 are owned by Cornerstone. Exxonmobil Inv Tx holds 200,543 shs. Jolley Asset Mngmt Llc holds 54,068 shs or 2.47% of its capital. Altfest L J Company owns 11,923 shs for 0.39% of their capital. Voya Inv Management Limited Liability Co accumulated 1.84 million shs. Nomura Hldgs holds 0.04% or 643,833 shs. Cohen Klingenstein Limited Liability Co accumulated 13,184 shs. Strategic Wealth Advsrs Grp Inc invested in 0.32% or 68,590 shs. Aldebaran Fincl Inc holds 0.9% of its capital in Gilead Sciences, Inc. (NASDAQ:GILD) for 17,730 shs. State Of Tennessee Treasury Department holds 759,706 shs or 0.29% of its capital. Texas Bancorp Tx accumulated 0.55% or 3,093 shs. Rothschild Asset Management Inc reported 0.65% stake. Covington Cap Mgmt accumulated 37,752 shs. Sand Hill Glob Advsr Limited Liability Com holds 0.47% or 6,397 shs in its capital.

Gilead Sciences, Inc. had 23 selling transactions and 0 insider buys since January 2, 2018. This’s net activity of $48.21 million. Another trade for 5,836 shs valued at $379,885 was sold by Cogan John Francis. $4.68 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) was sold by WILSON GAYLE E on Friday, February 9. Meyers James R also sold $8.02M worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Tuesday, January 16. Alton Gregg H also sold $1.11M worth of Gilead Sciences, Inc. (NASDAQ:GILD) shs. $401,566 worth of Gilead Sciences, Inc. (NASDAQ:GILD) was sold by Washington Robin L on Wednesday, February 21.

What Price Target Has Raymond James Given Gilead Sciences (NASDAQ:GILD)

Raymond James’s Equity research analysts have $93 price target which would indicate upside potential of 30.47 % on Gilead Sciences (NASDAQ:GILD). Raymond James also initiated coverage of GILD stock on 28 June.

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

A total of 16 analysts rate Gilead Sciences (NASDAQ:GILD) as follows: 11 “Buy”, 5 “Hold” and 0 “Sell”. Тherefore 69% are bullish. (NASDAQ:GILD) has 24 ratings reports on Jun 29, 2018 according to StockzIntelligence. In Tuesday, February 6 report Maxim Group maintained the stock with “Buy” rating. On Monday, February 12 the firm earned “Buy” rating by Mizuho. On Monday, January 29 the rating was maintained by Wells Fargo with “Buy”. On Monday, February 5 the company was maintained by Mizuho. On Tuesday, January 2 the firm has “Hold” rating by BMO Capital Markets given. On Wednesday, February 7 the firm has “Buy” rating by RBC Capital Markets given. On Wednesday, January 3 Credit Suisse maintained the shares of GILD in report with “Hold” rating. On Tuesday, January 30 the firm has “Buy” rating given by Citigroup. On Wednesday, May 30 the firm has “Buy” rating given by Piper Jaffray. On Wednesday, May 2 Leerink Swann maintained the shares of GILD in report with “Hold” rating.

The stock increased 1.35% or $0.95 during the last trading session, hitting $71.28.Currently Gilead Sciences, Inc. is uptrending after 4.37% change in last June 29, 2017. GILD has 1.76 million shares volume. GILD underperformed by 8.20% the S&P500.

Investors wait Gilead Sciences, Inc. (NASDAQ:GILD)’s quarterly earnings on July, 25., according to Faxor. Analysts predict $1.42 earnings per share. That’s $1.09 down or 43.43 % from 2017’s earnings of $2.51. If earnings per share of $1.42 is published the profit of GILD could hit $1.85 billion giving it 12.55 P/E. Wall Street predicts 3.65 % EPS growth as of July, 25.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally.The company has $92.68 billion market cap. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.27.11 is the P/E ratio. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging.

For more Gilead Sciences, Inc. (NASDAQ:GILD) news published briefly go to: Seekingalpha.com, Investorplace.com, Streetinsider.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Gilead: Growth Pick For Your Portfolio” published on June 15, 2018, “7 Best Dividend Stocks With Loads of Cash in the Bank” on June 28, 2018, “Gilead Sciences (GILD) Reports Positive Opinion from European CHMP for Yescarta (axicabtagene ciloleucel)” with a publish date: June 29, 2018, “Gilead Oncology CAR T-Cell Therapies Outlook Compelling” and the last “Gilead Sciences Is Too Cheap To Ignore – Cramer’s Lightning Round (6/22/18)” with publication date: June 25, 2018.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.